Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $35.71

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $35.71.

Several analysts recently commented on XNCR shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $32.00 price target on shares of Xencor in a research report on Wednesday, February 28th. Mizuho reduced their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 22nd. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. Piper Sandler restated a “neutral” rating and set a $24.00 price objective (down previously from $37.00) on shares of Xencor in a research report on Wednesday, February 28th. Finally, BMO Capital Markets cut their price objective on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 1,280 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total transaction of $30,080.00. Following the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at approximately $4,381,175.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP John R. Desjarlais sold 1,280 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a total transaction of $30,080.00. Following the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at approximately $4,381,175.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the transaction, the vice president now directly owns 161,675 shares in the company, valued at $3,133,261.50. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock valued at $2,152,417 in the last ninety days. 4.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D lifted its holdings in shares of Xencor by 24.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 110,353 shares of the biopharmaceutical company’s stock worth $2,224,000 after acquiring an additional 21,946 shares during the period. Hudson Bay Capital Management LP lifted its holdings in shares of Xencor by 144.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock worth $4,685,000 after acquiring an additional 137,500 shares during the period. Deutsche Bank AG lifted its holdings in shares of Xencor by 13.0% during the 3rd quarter. Deutsche Bank AG now owns 33,098 shares of the biopharmaceutical company’s stock worth $667,000 after acquiring an additional 3,805 shares during the period. Diversified Trust Co purchased a new position in Xencor in the fourth quarter valued at approximately $265,000. Finally, Illinois Municipal Retirement Fund purchased a new position in Xencor in the third quarter valued at approximately $707,000.

Xencor Trading Up 1.2 %

Shares of XNCR stock opened at $20.52 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36. The stock has a market capitalization of $1.25 billion, a P/E ratio of -9.77 and a beta of 0.76. The company has a 50 day moving average price of $22.18 and a 200 day moving average price of $20.40. Xencor has a fifty-two week low of $16.49 and a fifty-two week high of $30.21.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67). The company had revenue of $44.70 million for the quarter, compared to analysts’ expectations of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The firm’s quarterly revenue was up 106.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.20) EPS. Equities research analysts predict that Xencor will post -3.24 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.